Delcath Systems Inc (NASDAQ:DCTH)

0.961
Delayed Data
As of 11:31am ET
 -0.009 / -0.93%
Today’s Change
0.92
Today|||52-Week Range
4.96
-20.58%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$11.8M

Company Description

Delcath Systems, Inc. is a pharmaceutical and medical device company, which is focused on oncology and liver cancer therapy. Its proprietary drug and device combination product, Delcath Hepatic Delivery System is designed to administer high dose chemotherapy and other therapeutic agents to the liver, while controlling the systemic exposure of those agents. The company also initiated plans to investigate the Melblez kit for primary liver cancer; and focuses on the treatment of primary and metastatic liver cancers. Its proprietary product also delivers and filters melphalan hydrochloride under the trade name Delcath Hepatic CHEMOSAT Delivery System. Delcath Systems was founded on August 5, 1988 and is headquartered in New York, NY.

Contact Information

Delcath Systems, Inc.
810 Seventh Avenue
New York New York 10019
P:(212) 489-2100
Investor Relations:

Employees

Shareholders

Other institutional7.74%
Mutual fund holders2.94%
Individual stakeholders0.96%

Top Executives

Jennifer K. SimpsonPresident & Chief Executive Officer
Barbra C. KeckChief Financial Officer, CAO, VP & Controller
J. Chris HouchinsSenior Vice President-Clinical & Medical Affairs
Gloria LeeExecutive VP-Clinical & Medical Affairs
Seymour FeinMedical Director-Scientific Advisory Board

To view my watchlist

Not a member yet?

Sign up now for a free account